Picard Medical Surges on Successful In Vivo Implant Studies for Emperor TAH

Picard Medical announced on June 2, 2026, that its Emperor Total Artificial Heart (TAH) met all primary endpoints in a pivotal in vivo implant study, sending its shares sharply higher in premarket trading. The device demonstrated reliable hemodynamic support and biocompatibility over a 90-day period in preclinical models, clearing a key regulatory pathway toward first-in-human trials. The study, conducted at three U.S. research centers, showed no device failures or thromboembolic events in the implanted cohort. Picard stock (NASDAQ: PIC) climbed 18% to $24.70 as of 10:00 a.m. ET, extending a 40% year-to-date gain. Analysts said the data significantly de-risks the technology, though commercialization remains years away. The company expects to file an investigational device exemption with the FDA by September 2026.